After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research this area.
Can psychedelic compounds play a part in drug dependence therapy? | The British Journal of Psychiatry
von pgd | Mai 30, 2017 | Forschung | 0 Kommentare